StagingTesting mode — staging environment. No real money: balances, trades, and accounts are for testing only and may be reset at any time.DEMODemo mode: simulated data, for showcase only

GLP-1 obesity market leader end of 2026?

Price and outcomes

About This Market

Predicts the obesity/GLP-1 franchise with the largest reported sales in Q4 2026. Resolves to the company with the highest obesity-drug revenue for the quarter. Source: company earnings reports.

Quality scoreNot yet rated

Source

Official announcement or authoritative source

Activity and discussion

No comments yet

GLP-1 obesity market leader end of 2026?

Amount

Slide to Buy Yes

Related Markets

View all

FDA approves Novo's CagriSema in 2026?

41¢

-2%

$654.2K

WHO declares an H5N1 pandemic in 2026?

43¢

+12%

$544.3K

FDA approves a new CRISPR therapy in 2026?

44¢

-7%

$288.3K

Tech & Science·Health & Biotech

GLP-1 obesity market leader end of 2026?

Price and outcomes

GLP-1 obesity market leader end of 2026?

About This Market

Predicts the obesity/GLP-1 franchise with the largest reported sales in Q4 2026. Resolves to the company with the highest obesity-drug revenue for the quarter. Source: company earnings reports.

Quality scoreNot yet rated

Source

Official announcement or authoritative source